Invesco
BCAX

Invesco’s Bicara Therapeutics BCAX Stock Holding History

Invesco’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.29M Buy
43,389
+11,739
+37% +$262K ﹤0.01% 2791
2026
Q1 		$630K Buy
31,650
+10,644
+51% +$183K ﹤0.01% 3063
2025
Q4 		$354K Buy
21,006
+3,595
+21% +$61.4K ﹤0.01% 3327
2025
Q3 		$275K Buy
17,411
+534
+3% +$5.98K ﹤0.01% 3451
2025
Q2 		$157K Buy
16,877
+1,962
+13% +$23.4K ﹤0.01% 3574
2025
Q1 		$194K Sell
14,915
-409
-3% -$5.43K ﹤0.01% 3518
2024
Q4 		$267K Buy
+15,324
New +$319K ﹤0.01% 3451

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco's BCAX Position: Q2 2026 in Review

Invesco increased its Bicara Therapeutics (BCAX) stake by 37% in Q2 2026, buying an estimated $262K and bringing the position to 43,389 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #2791.

Invesco first reported a position in BCAX in Q4 2024 and has held it in 7 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Invesco held 43,389 shares of Bicara Therapeutics worth $1.29M as of Q2 2026.
  • Invesco bought 11,739 Bicara Therapeutics shares in Q2 2026, an estimated $262K.
  • Bicara Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2791 holding.
  • Invesco first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.